secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001213900-24-029318
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx reports preliminary Q4 GAAP net loss of $7.2M, extends audited financials deadline
--------------------------------------------------------------------------------

- GAAP net loss for Q4 2023 was $7.2M vs $0.3M loss in Q4 2022; FY2023 net loss $20.6M vs $11.4M.
- Adjusted EBITDA for Q4 2023 was $5.8M vs $3.9M; FY2023 Adjusted EBITDA $3.6M vs $5.5M.
- Recorded $6.7M asset impairment and $2.1M loss on disposal of business in Q4 2023.
- Lenders extended deadline for audited FY2023 financial statements to April 15, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024029318/0001213900-24-029318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024029318/ea0203141-8k_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-029318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer